Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

L'étude INITIATE : initiation du traitement de la dépendance à la nicotine pour les fumeurs admis aux urgences (INITIATE)

30 octobre 2026 mis à jour par: Ottawa Heart Institute Research Corporation

The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

1208

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Ontario
      • Ottawa, Ontario, Canada
        • Recrutement
        • University of Ottawa Heart Institute
        • Contact:
      • Ottawa, Ontario, Canada
        • Recrutement
        • Civic Hospital
        • Contact:
          • Dr. Venkatesh Thiruganasambandamoorthy
          • Numéro de téléphone: 6137985555,17023
          • E-mail: vthirug@toh.ca
      • Ottawa, Ontario, Canada
        • Recrutement
        • General Hospital
        • Contact:
          • Dr. Venkatesh Thiruganasambandamoorthy
          • Numéro de téléphone: 6137985555,17023
          • E-mail: vthirug@toh.ca
      • Ottawa, Ontario, Canada
        • Recrutement
        • Riverside Hospital
        • Contact:
          • Dr. Venkatesh Thiruganasambandamoorthy
          • Numéro de téléphone: 6137985555,17023
          • E-mail: vthirug@toh.ca

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Current daily smoker (smokes ≥ 5 cigarettes per day);
  • ≥ 18 years of age (the age of majority in Ontario);
  • For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
  • Able to read and understand English or French;
  • Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
  • Available and willing to participate in follow-up assessments over the next 12 months;
  • Has access to a telephone or computer;
  • Able to provide informed consent

Exclusion Criteria:

  • Currently participating in this or another smoking cessation study;
  • For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
  • Pregnant, planning to become pregnant over the next year, or breastfeeding;
  • Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
  • In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
  • Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Quit Card Intervention (QCI)

Study intervention group.

The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a "Quit Card" (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist.

Aucune intervention: Usual Care (UC)

Study control group.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Smoking Abstinence
Délai: 26 weeks (6 months) after study enrollment

Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test

26 weeks (6 months) after study enrollment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Prolonged Abstinence
Délai: 4, 26, and 52 weeks after study enrollment

Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Point Prevalence Abstinence
Délai: 4, and 52 weeks after study enrollment

Point prevalence smoking abstinence, at 4, and 52 weeks

4, and 52 weeks after study enrollment
Smoking Reduction
Délai: 4, 26, and 52 weeks after study enrollment

Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Number of Quit Attempts
Délai: 4, 26, and 52 weeks after study enrollment

Number of quit attempts since study entry, at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Cessation Medication and/or E-cigarette Use
Délai: 4, 26, and 52 weeks after study enrollment

Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Use of Behavioural Supports
Délai: 4, 26, and 52 weeks after study enrollment

Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Health-Related Quality of Life
Délai: 52 weeks after study enrollment

Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

52 weeks after study enrollment
Health Services Outcomes - ED visits
Délai: 4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Health Services Outcomes - Hospital Admissions
Délai: 4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Health Services Outcomes - Deaths
Délai: 4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Cost-Effectiveness Ratios
Délai: 52 weeks after study enrollment

Cost-effectiveness ratios related to health services at 52 weeks

52 weeks after study enrollment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Kerri-Anne Mullen, PhD, Ottawa Heart Institute Research Corporation

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

19 avril 2022

Achèvement primaire (Estimé)

1 septembre 2027

Achèvement de l'étude (Estimé)

1 septembre 2027

Dates d'inscription aux études

Première soumission

7 octobre 2019

Première soumission répondant aux critères de contrôle qualité

13 novembre 2019

Première publication (Réel)

14 novembre 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner